🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#Angioedema is swelling underneath the skin. Join #HCWCO at the 1st Annual Hereditary Angioedema (HAE) Virtual Conference on July 20, 2022. Click here to register: bit.ly/3xVcWP7

The #HCWCO equity research team delivers insights on a wide range of #CleanTech, Alternative Energy, and Environmental Solutions companies. Review our Clean Tech coverage universe here: bit.ly/3F1q4Ux #ESGinvestors #institutionalinvestors

June 29th, join us at the #HCWCO Preclinical Cancer Drug Discovery: Emerging Targets and Modalities. bit.ly/3mI2zrj #institutionalinvestor

#HCWCO is a #capitalmarkets, analysis-driven, full service #investmentbank. Our expert #investmentbanking team facilitates a diverse range of transactions. Learn more about our capabilities: bit.ly/3vcePCC

You couldn't attend? Don't worry, visit the #HCWCO Media Room. Find #investorpresentations along with recordings of #KOL events and our Weekly #PsychedelicsPodcast here: bit.ly/2SfRWA7

Tomorrow, don't miss the 1st Annual #HCWCO Mental Health Conference: Neuropsychiatry, Psychedelics, and Beyond. Click here to register: bit.ly/3awZsNi #psychedelicsinvestors #investors

Today is the day. #HCWCO 1st Annual #MentalHealth Conference: Neuropsychiatry, Psychedelics, and Beyond. Click the link to join virtually: bit.ly/3awZsNi

The #HCWCO #EquityResearch team covers 640+ public companies in Life Sciences & #Healthcare, Metals & Mining, #CleanTech, Technology, Financial Technology & #Cryptocurrency. See our coverage here: bit.ly/32hCBR

Tomorrow join us for the #HCWCO Preclinical Cancer Drug Discovery: Emerging Targets and Modalities – Virtual Conference. Click the link to register and learn more! bit.ly/3mI2zrj

Headquartered in #NewYorkCity & servicing a global client base. Our #HCWCO team has a keen sense of trends across all potential market landscapes: bit.ly/3oatLPp

Update on #InflaRx ($IFRX): According to the FDA website, Vilobelimab has been granted Orphan Drug Designation for the treatment of pyoderma gangrenosum. More in the #HCWCO Morning Summary; bit.ly/3sxypaP #HealthcareInvestors

Our #corporateaccess team hosts #institutionalinvestor events throughout the year. See our recent and upcoming events here: hcwevents.com

Save the date and register! #HCWCO 2nd Annual Ophthalmology Virtual Conference is around the corner. August 17, 2022. Learn more here: bit.ly/2TUxQfJ

Join our team of industry and #financialprofessionals. Learn more about a career at #HCWCO here: bit.ly/3wMEfJB #investmentbank

Our #investmentbanking team continues to execute transactions. Learn more by clicking here: bit.ly/32obGmF #HCWCO

Catch up on the #HCWCO #psychedelics podcast by accessing the #HCWCOMediaRoom here: bit.ly/2SfRWA7

Save the date! #HCWCO Private Company Showcase Aug 2-4, 2022 In-Person Conference! Learn more: bit.ly/3mGCby0

We are initiating coverage on @theseusrx ($THRX) which is focused on developing pan-inhibition treatments for gastrointestinal stromal tumors. Read more in the #HCWCO Morning Summary; bit.ly/3sxypaP #HealthcareInvestors

We are initiating coverage on NRx Pharmaceuticals ($NRXP) which is focused on therapies for central nervous system disorders and life-threatening respiratory diseases. More in the #HCWCO Morning Summary; bit.ly/3sxypaP #PharmaInvestors

We are initiating coverage on Acumen Pharmaceuticals, Inc. ($ABOS) a clinical-stage company developing a novel disease-modifying approach to Alzheimer's disease. Details in the #HCWCO Morning Summary; bit.ly/3sxypaP #BiopharmaInvestors